Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0228)
Name
Ginkgolide B
Synonyms
Ginkgolide B; 15291-77-7; Ginkolide B; Gingko lactone; BN 52021; SR-01000597598; bn52021; Ginklide B; 7-Deoxyginkgolide C; CHEMBL266625; SCHEMBL14279903; 1-Hydroxy-(1beta)-Ginkgolide A; BCP25992; NSC110257; PDSP1_000734; PDSP2_000724; AKOS015895882; NSC-110257; tert-butyl-trihydroxy-methyl-[?]trione; NCGC00025245-01; 99796-69-7; AS-56165; L000993; SR-01000597598-1; SR-01000597598-3; 8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione

    Click to Show/Hide
Status
Terminated
Drug Type
Small molecular drug
Structure
3D MOL
2D MOL
Formula
C20H24O10
IUPAC Name
8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
Canonical SMILES
CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O
InChI
InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3
InChIKey
SQOJOAFXDQDRGF-UHFFFAOYSA-N
PubChem CID
65243
TTD Drug ID
D04ZCZ
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Nonalcoholic fatty liver disease ICD-11: DB92
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
In Vivo Model
Male 8-week-old C57/BL6 ApoE-/-mice of weight (22~25 g) were purchased from Changzhou Cavens experimental animal Co., Ltd (Jiangsu, China). After 5 weeks of feeding, HFD-fed mice were randomly assigned into 4 groups (n = 10) : HFD group (0.9 % sodium chloride by gavage), GB-L group (at a high dose of 20 mg kg-1d-1 GB in 0.9 % sodium chloride by gavage), GB-H group (at a high dose of 30 mg kg-1d-1 GB in 0.9 % sodium chloride by gavage), and Ato group (1.3 mg kg-1d-1 Ato in 0.9 % sodium chloride by gavage) as a positive control. The mice in ND group were given the same volume of 0.9 % sodium chloride.

    Click to Show/Hide
Response regulation Ginkgolide B (GB), a main constituent of Ginkgo biloba extracts, reduces hepatic lipid accumulation and ameliorates nonalcoholic fatty liver disease (NAFLD) in obese mice. Remarkably, after Nrf2 interference, GB treatment significantly increased Nrf2 expression, indicating that GB exerted anti-ferroptosis effects by activation of Nrf2 pathway.
References
Ref 1 Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease. Toxicology. 2020 Dec 1;445:152599. doi: 10.1016/j.tox.2020.152599. Epub 2020 Sep 22.